Algunos fragmentos del mismo link que pasaste:
“However, proper evaluation of the safety and efficacy of each of these two vaccines, the duration of protection, and their effectiveness in the elderly, must await publication of the full data on the trials”
““However, despite these differences (and one cannot help speculating why the Gemaleya Centre chose to release data relatively early, one day after the release of the Pfizer data), the date are encouraging, and suggest this vaccine is also effective, although the numbers are too small to be sure of this yet.”
““Interim analyses are commonly performed in clinical trials, but in order to protect statistical rigour, they should be pre-planned prior to the analysis of the results. The Gameleya centre did not provide the protocol so we do not know if this interim analysis was pre-planned, but in view of its small size, I would assume not. Although the lack of pre-planning could weaken the data package when it comes to a regulatory submission”
"These were healthcare and front line workers. They report an efficacy rate of over 90% in this group also, although no details of how these results were obtained – for example whether there was a control group who did not receive vaccine, without which its impossible to calculate the efficacy rate. These data are therefore difficult to interpret and little weight should be attached to them until more details are known. "
“The analyses presented today are very early results based on just 20 confirmed infections so the exact efficacy remains uncertain until the final analyses.”
“The press release text is a little confusing such that we cannot easily determine the number of individuals that have received the vaccine/placebo from which the efficacy data are derived”
"We still do not know whether there is any impact on the pattern of break through disease in vaccinated vs unvaccinated subjects and the impact, if any, on infection and transmission, which will impact the use of vaccines in populations.”
“Whilst encouraging, I worry that these data have been rushed out on the back of the Pfizer/BioNtech announcement earlier in the week. The Sputnik data are based on only 20 cases of COVID-19 in the trial participants, compared to more than 90 cases in the earlier trial.
“This is not a competition. We need all trials to be a carried out to the highest possible standards and it is particularly important that the pre-set criteria for unblinding the trial data are adhered to avoid cherry picking the data. Anything less than this risks a public loss of trust in all vaccines, which would be a disaster.”
“The consequence is that there is considerable uncertainty because of the small number (20) of total Covid-19 cases. Further follow-up is needed because the results are compatible with a much lower efficacy (60%) based on these data."
“The Sputnik efficacy has also been estimated, though far less reliably than in the randomised trial, using a group without a comparator of 10,000.”
“The full report should give more detail on how the follow-up was done and how the trial was monitored.
““However, again it will be necessary to see the complete data set before making confident assessments of how well this”
No se que tanto entenderás de inglés pero esos fragmentos dicen exactamente lo contrario a tu mensaje.
Si para defender a la vacuna rusa tienen que venir a mentir, es porque está muy floja de papeles muchachos…